Abstract
Kv7 channels are unique among K+ channels, since four out of the five channel subtypes have well-documented roles in the development of human diseases. They have distinct physiological functions in the heart and in the nervous system, which can be ascribed to their voltage-gating properties. The Kv7 channels also lend themselves to pharmacological modulation, and synthetic openers as well as blockers of the channels, regulating neuronal excitability, have existed even before the Kv7 channels were identified by cloning. In the present review we give an account on the focused efforts to develop selective modulators, openers as well as blockers, of the Kv7 channel subtypes, which have been undertaken during recent years, along with a discussion of the Kv7 ion channel physiology and therapeutic indications for modulators of the neuronal Kv7 channels.
Keywords: spike-frequency adaptation (SFA), BMS204352, Retigabine, atomic absorption assay, Epilepsy, Migraine, Pain
Current Topics in Medicinal Chemistry
Title: Kv7 Channels: Function, Pharmacology and Channel Modulators
Volume: 6 Issue: 10
Author(s): William Dalby-Brown, Henrik H. Hansen, Mads P.G. Korsgaard, Naheed Mirza and Soren-P Olesen
Affiliation:
Keywords: spike-frequency adaptation (SFA), BMS204352, Retigabine, atomic absorption assay, Epilepsy, Migraine, Pain
Abstract: Kv7 channels are unique among K+ channels, since four out of the five channel subtypes have well-documented roles in the development of human diseases. They have distinct physiological functions in the heart and in the nervous system, which can be ascribed to their voltage-gating properties. The Kv7 channels also lend themselves to pharmacological modulation, and synthetic openers as well as blockers of the channels, regulating neuronal excitability, have existed even before the Kv7 channels were identified by cloning. In the present review we give an account on the focused efforts to develop selective modulators, openers as well as blockers, of the Kv7 channel subtypes, which have been undertaken during recent years, along with a discussion of the Kv7 ion channel physiology and therapeutic indications for modulators of the neuronal Kv7 channels.
Export Options
About this article
Cite this article as:
Dalby-Brown William, Hansen H. Henrik, Korsgaard P.G. Mads, Mirza Naheed and Olesen Soren-P, Kv7 Channels: Function, Pharmacology and Channel Modulators, Current Topics in Medicinal Chemistry 2006; 6 (10) . https://dx.doi.org/10.2174/156802606777323728
DOI https://dx.doi.org/10.2174/156802606777323728 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Regulation of Brain Nucleoside Utilization
Current Metabolomics Editorial (Thematic Issue: GABAergic Modulation as Treatment Strategy: Consideration of Several Diseases)
Current Pharmaceutical Design Computational Protein-Protein Docking Reveals the Therapeutic Potential of Kunitz-type Venom against hKv1.2 Binding Sites
CNS & Neurological Disorders - Drug Targets Cell Biological Consequences of Mitochondrial NADH: Ubiquinone Oxidoreductase Deficiency
Current Neurovascular Research Melatonin Receptor Agonists: SAR and Applications to the Treatment of Sleep-Wake Disorders
Current Topics in Medicinal Chemistry Resveratrol in Medicinal Chemistry: A Critical Review of its Pharmacokinetics, Drug-Delivery, and Membrane Interactions
Current Medicinal Chemistry Lithium in Psychiatry-The Benefits and Risks Associated with the Lithium Salts Treatment in Affective Disorders
Current Psychopharmacology Alpha7 Neuronal Nicotinic Receptor: A Pluripotent Target for Diseases of the Central Nervous System
CNS & Neurological Disorders - Drug Targets Lipid Matrix Nanoparticles: Pharmacokinetics and Biopharmaceutics
Current Nanoscience Subject Index to Volume 9
Current Pharmaceutical Design Synthesis and Preliminary Biological Evaluation of New Heterocyclic Carboxamide Models
Letters in Drug Design & Discovery Brivaracetam Prevents the Over-expression of Synaptic Vesicle Protein 2A and Rescues the Deficits of Hippocampal Long-term Potentiation In Vivo in Chronic Temporal Lobe Epilepsy Rats
Current Neurovascular Research The Role of IRE1 Signaling in the Central Nervous System Diseases
Current Neuropharmacology Synthesis and DPPH Radical Scavenging Activity of 5-Arylidene-N,Ndimethylbarbiturates
Medicinal Chemistry Current Overview of Inorganic Nanoparticles for the Treatment of Central Nervous System (CNS) Diseases
Current Nanomaterials Synthesis and Anticonvulsant Activity Evaluation of 6-phenyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines
Letters in Drug Design & Discovery Synthesis, Anticonvulsant and Antimicrobial Activities of Some New [1-(2-Naphthyl)-2-(pyrazol-1-yl)ethanone]oxime Ethers
Medicinal Chemistry Target Based Drug Design - A Reality in Virtual Sphere
Current Medicinal Chemistry Editorial [Hot Topic: PET and SPECT in Drug Evaluation and Drug Design Imaging Inflammatory Processes, Tumors, and the Endocannabinoid System(Executive Editor: Aren van Waarde)]
Current Pharmaceutical Design AMPA Receptor Antagonists for the Treatment of Stroke
Current Drug Targets - CNS & Neurological Disorders